Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex ( R)) in advanced colorectal cancer

By Farrugia D.C.   Norman A.R.   Cunningham D.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 987-991

Elsevier

Access to resources Recommend Favorite

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

By Pfeiffer Per   Nielsen Dorte   Yilmaz Mette   Iversen Anja   Vejlø Christian   Jensen Benny Vittrup  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 697-701

Informa Healthcare

Access to resources Recommend Favorite

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial

By Buchholz Thomas  

The Women's Oncology Review, Vol. 5, Iss. 1, 2005-03 ,pp. : 53-55

Informa Healthcare

Access to resources Recommend Favorite

Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer

By Goto Ayumu   Yamada Yasuhide   Hosokawa Ayumu   Ura Takashi   Arai Tatsuhiro   Hamaguchi Tetsuya   Muro Kei   Shimada Yasuhiro   Shirao Kuniaki  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 364-368

Springer Publishing Company

Access to resources Recommend Favorite

Irinotecan and 5-Fluorouracil in colorectal cancer: time for a pause?

By Bulusu V.R.  

European Journal of Cancer, Vol. 34, Iss. 3, 1998-02 ,pp. : 286-289

Elsevier

Access to resources Recommend Favorite